Dabrafenib and trametinib have certain beneficial effects on ATC, melanoma, and fibrosarcoma patients with BRAF mutations [12,44,45], because they act as BRAF and MEK inhibitors by significantly inhibiting the activation of downstream proteins of the MAPK pathway [12,46]. Here, MAP2K7 is linked to melanoma.